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Available online 26 January 2016Antiretroviral therapy (ART) has led to dramatic improvements in the lives of HIV-infected persons. However, re-
sidual immune activation, which persists despite ART, is associated with increased risk of non-AIDS morbidities.
Accumulating evidence shows that disruption of the gut mucosal epithelium during SIV/HIV infections allows
translocation of microbial products into the circulation, triggering immune activation. This disruption is due to
immune, structural andmicrobial alterations. In this review, we highlighted the key ﬁndings of gut mucosa stud-
ies of SIV-infected macaques and HIV-infected humans that have revealed virus-induced changes of intestinal
CD4, CD8 T cells, innate lymphoid cells, myeloid cells, and of the local cytokine/chemokine network in addition
to epithelial injuries. We review the interplay between the host immune response and the intestinal microbiota,
which also impacts disease progression. Collectively, these studies have instructed clinical research on early ART
initiation, modiﬁers of microbiota composition, and recombinant cytokines for restoring gut barrier integrity.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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The human gastrointestinal (GI) tract has coevolved with billions of
commensal microorganisms that are considered by many immunolo-
gists to be an “extended self” (Reynolds et al., 2015). This symbiotic
relationship between microorganisms and the host requires efﬁcient
barrier and tolerance mechanisms that preserve intestinal immune
balance and tissue integrity. HIV infection leads to disruption of both
immunebalance and epithelial barrier integrity, contributing to residual
immune activation (Younas et al., 2015). Such immune activation per-
sists despite ART and is associated with an increased risk of non-AIDS
morbidities, such as cardiovascular diseases and neurocognitive
disorders. This persistent immune activation is thought to originate
from latently infected cells contributing to residual HIV expression,
and gut barrier damage. Cumulative evidence indicates that multiple
events occur within the GI tract of pathogenically Simian Immunodeﬁ-
ciency Virus (SIV)-infected Asian macaques and HIV-infected individ-
uals (Estes et al., 2010; Brenchley, 2013). These events cause increased
intestinal permeability, resulting in the translocation of bacterial
products of the GI microﬂora through the epithelial barrier and into
the systemic circulation. This microbial translocation is considered to
be amajor driver of chronic immune activation and disease progression,
even in patients receiving ART (Brenchley et al., 2006; Vyboh et al.,
2015).
Our understanding of SIV- and HIV-induced immune gut damage
was primarily based on CD4 T cell studies, with changes in CD8 T cells
and myeloid populations being relatively less studied. Herein, we
highlight the key ﬁndings of gut mucosa studies of SIV-infected rhesus
macaques (RMs) and HIV-infected subjects that have revealed changes
in the distribution of Th17, Treg, Th22, CD8 T cells, innate lymphoid cells
and myeloid cells, in addition to the disruption of the local cytokine/
chemokine network. We also review studies describing SIV/HIV-
induced injuries to the intestinal epithelium, changes in the composi-
tion of the gut microbiota, and/or translocation of gut microbial
products. Our ﬁndings underline the importance of designing novel
therapies that target microbial composition and gut barrier integrity
to further control immune activation that in turnwill improve the qual-
ity of life of HIV-infected individuals, while potentially reducing the size
of the HIV reservoir.
2. Gut Damage in Conditions Other Than HIV: Learning From “Out-
side the Box”
Early in theHIV pandemic, GI dysfunctionswere reported in patients
progressing to AIDS. These dysfunctions included nutrient malabsorp-
tion, diarrhea and weight loss, all of which pointed to a link between
the disruption of immune homeostasis and gut damage (Kotler et al.,
1984). Initial descriptions of the pathological changes observed in pa-
tients with advanced HIV infection evoked GI manifestations of Crohn's
disease and ulcerative colitis, two major forms of inﬂammatory bowel
disease (IBD), (Ho et al., 2014). Both IBD and HIV infections can be con-
sidered as conditions involving a breakage in the mutualism between
the host and the gut microbiota. Graft-versus-host disease (GVHD) is
also characterized by features of gut damage including immunosup-
pression, alteration of the composition of the intestinal microbiota,and microbial translocation, all of which lead to systemic inﬂammation
(Jenq et al., 2012).
These ﬁndings raise questions regarding the determinants of
immune tolerance towards the intestinal microbiota. Due to limitations
in assessing mucosal immune responses in patients, non-human
primate (NHP) models of SIV-related gut damage have played a critical
role in understanding the interplay between microbiota, gut barrier
integrity and systemic immune responses. In this review, we synthesize
the studies of mucosal immunity in NHP models and discuss their
relevance to HIV pathogenesis.
3. Gut Damage in SIV Infection: A Mucosal Tragedy
3.1. Non-human Primate Models of HIV/AIDS
Macaques that develop an AIDS-like disease following experimental
SIV infection include rhesus (Macaca mulatta), cynomolgus (Macaca
fascicularis), and pigtail (Macaca nemestrina) macaques. The RM
model is the most extensively studied and includes the Indian and
Chinese subtypes; the Indian subtype experiences faster disease pro-
gression compared to the Chinese subspecie (reviewed in Zhou et al.,
2013). In contrast to progressive SIV infection of Asian macaques, over
40 known species of African non-human primates are endemically in-
fected (Chahroudi et al., 2012). These natural hosts of SIV, which remain
asymptomatic, are characterized by a low level of immune activation
despite highly replicating virus. Among these species, sooty mangabeys
(SMs) and African green monkeys (AGMs) have been extensively
studied as nonpathogenic models. Progressive and nonpathogenic
models have contributed to our understanding of mucosal immunity
and immune activation during SIV infection.
The gutmucosal immune system of NHP and humans is divided into
inducible and effector compartments. The inducible sites are composed
of organized lymphoid structures such as Peyer's patches and isolated
lymphoid follicles (Brandtzaeg et al., 2008). The effector sites,
comprised of the epithelium lining the gut lumen and the subjacent lam-
ina propria (LP), contain diffusely distributedmyeloid and lymphoid cells.
3.2. CD4 T Cell Depletion: Targeting the “Helpers”
Mucosal CD4 T cell depletionwas ﬁrst reported in AIDS patients; this
depletion was predominant in the duodenum (Rodgers et al., 1986),
suggesting differential impact of HIV infection along the intestine. CD4
T cell changes in early SIV infection were subsequently investigated in
NHP models; key study ﬁndings are summarized in Table 1. In Indian
RMs, enteropathies were reported by Veazey et al. who observed the
depletion of 80% to 90% of activated CD4 T cells in the gut mucosa at
day 14 post-infection (Veazey et al., 2000). In Chinese RMs, rectal
CD4+ T cells were depleted by 30% at day 14 post-infection, although
no changes were observed in the small intestine (Couëdel-Courteille
et al., 2003). In these studies, mucosal helper T cell depletion was
assessed by measuring CD4 T cell frequencies, which is inﬂuenced by
the size of other cell populations. Therefore, immunostaining was per-
formed in subsequent studies. The colon of Indian RMs showed up to
50% depletion of CD4 T cells (Li et al., 2005); in newly HIV-infected
individuals, CD4 T cell depletion was detected in the effector sites of
Table 1
Studies of intestinal CD4 T cell, CD8 T cell, and myeloid cell distribution during SIV infection of rhesus macaques.
Gut segment Methods Time
post-infection
CD4 T cells CD8 T cells Myeloid cells References
Jejunum FC Day 14 to 63 80–90% depletion of CD4+
CCR5+ T cells
NA NA Veazey et al., 2000
Rectum
S.I.
FC, IHC Day 14 30% depletion
of LP CD4+ T cells
No depletion
NA NA Couëdel-Courteille et al.,
2003 (Ch)
Colon IHF Day 14 50% depletion of
CD4 T cells
NA NA Li et al., 2005
Jejunum FC Chronic Th17+ Th22+ depletion NA NA Xu et al., 2014 (In)
Jejunum FC Acute and chronic CD4 T cell depletion NA NA Glavan et al., 2015
Jejunum,
ileum, colon
FC Day 7
Days 14, 21, 50
30–50% depletion of
LP CD4+ CD25+ T cells
80–90% depletion of
LP CD4+ CD25+ T cells
10–20% increase
(jejunum and colon)
10–50% increase
(greatest in the ileum)
NA Veazey et al., 1998
Jejunum FC Days 3, 7, 10, 14
Days 14, 17
80% depletion of CD4+
CD45RA− CCR5+ T cells
Increased frequency of total
CD8 T cells
NA Mattapallil et al., 2005
Rectum
S.I., colon
FC
FC
Day 14 to week 6
Chronic
Decrease in CD4 Treg
NA
Expansion of total CD8
and CD8+ FOXP3+ T cells
Increased frequency of CD8+
FOXP3+ T cells
NA Nigam et al., 2010
Colorectal biopsies FC Acute
Chronic NA
Maintenance of Tc17 cells
Loss of Tc17 cells
NA Nigam et al., 2011
Jejunum FC
IHC
Day 21
Chronic
NA
NA
Increase of ILC-17 cells
Decreased numbers of Tc17
and ILC-17 cells
NA
NA
Xu et al., 2012
Jejunum FC Day 8, 10
Day 13
Depletion of LP BrdU+
CD4 T cells
Increased numbers
of LPL BrdU+ CD8 T cells
NA Wang et al., 2013
Colon IHC Chronic NA NA Neutrophil
inﬁltration (myeloperoxidase+)
Estes et al., 2010
(In)
Colon FC Chronic Loss of Th17 cells Decreased frequency of Tc17 cells Loss of CD103+ DCs;
No change in the frequency
of mDCs or pDCs
Klatt et al., 2012
Colon, rectum FC, IHF Chronic NA NA 4-fold increase in the
number of CD123+ pDCs
No change in the number
of mDCs
Reeves et al., 2012 (In)
Rectum FC
IHC
Day 14
Week 4
Decrease in
CD4+ IL-17+ T cells
NA
Neutrophil inﬁltration
(myeloperoxidase+)
Pallikkuth et al., 2013
Ileum IHF Days 3, 7, 10, 14 NA Increased numbers of LP CD8 T cells Changes of macrophage counts Ponte, 2014 (Ch)
S.I.: small intestine; FC: ﬂow cytometry; IHC: immunohistochemistry; IHF: immunohistoﬂuorescence; LP: lamina propria; DCs: dendritic cells; mDCs: myeloid-derived dendritic cells;
pDCs: plasmacytoid dendritic cells; Tc17: IL-17 producing CD8 T cells; (Ch): rhesus macaque of Chinese origin and (In): rhesusmacaque of Indian origin, when applicable; NA: not appli-
cable. Studies are classiﬁed chronologically and according to the cell type.
Table 2
Studies that assessed changes in immune-cell distribution in the gut of HIV-infected persons.
Gut segment Methods Estimated time post-infection ART status Changes References
Rectum IHC Early Naïve Decreased CD4/CD8 ratio Mehandru et al. (2004)
Duodenum FC Chronic Naïve Increased number and frequency of Treg Epple et al. (2006)
Rectum FC Chronic Untreated Depletion of Th17 cells Shaw et al. (2011)
Increased Treg frequency
Duodenum IHC Chronic Naïve Accumulation of CD68+ and CD163+ macrophages Allers et al. (2014)
Duodenum IHC Hyper acute Naïve No depletion of CD4 T cells Allers et al. (2015)
Higher CD8 T cell numbers
Chronic Naïve Depletion of CD4 T cells
Increased number of CD8 T cells
Accumulation of monocytes
Colon IHC AIDS Naïve Accumulation of CD14+ macrophages Cassol et al. (2015)
Colorectal tissue IHC Chronic ART-treated and untreated Neutrophil inﬁltration Somsouk et al. (2015)
IHC: immunohistochemistry; FC: ﬂow cytometry; ART: antiretroviral therapy.
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precisely quantify T cell numbers in small biopsies (Mehandru et al.,
2004). In contrast, no change was observed in the duodenum during
acute HIV infection (Allers et al., 2015) and in the ileum of acutely
SIV-infected Chinese RMs (Ponte, 2014), suggesting that a reduction
in the absolute numbers of CD4 T cells may be less dramatic during
very early HIV infection and less pathogenic SIVmodel. The key ﬁndings
that examined the effect of HIV on gut CD4 T cell numbers are summa-
rized in Table 2.
Most of the CD4 T cells depleted by SIV/HIV are memory cells that
express CCR5, one of the main co-receptors for SIV/HIV entry
(Mattapallil et al., 2005). Functional studies have shown the impair-
ment of Th17 and Th22 subsets involved in the maintenance of gut
barrier integrity in both acute (Pallikkuth et al., 2013) and chronic
SIV/HIV infections (Klatt et al., 2012; DaFonseca et al., 2015; Xu et
al., 2014). The loss of intestinal CD4 T cells was also reported in non-
pathogenic SIV infections, although Th17 subsets in the LP were pre-
served (Chahroudi et al., 2012). In addition, a transient loss of
mucosal Foxp3+ Treg was observed in the pathogenic SIV infection
of pigtail macaques (Favre et al., 2009) and RMs (Nigam et al.,
2010); these cells were not lost in AGMs, which are natural SIV
hosts, demonstrating that an altered Th17/Treg ratio characterizes
pathogenic SIV infection. In chronic HIV infection, Th17 cells were
massively depleted while Treg frequency increased in the gut muco-
sa (Shaw et al., 2011; Epple et al., 2006). Overall, these results show
that impairment of intestinal Th17/Th22 cells is associated with sys-
temic immune activation, shedding light on the importance of the
gut damage that occurs in early HIV infection.3.3. The CD8 T Cell Compartment: Under the Shadow of the Almighty CD4 T
Cells?
Most studies of SIV/HIV-induced gut damage have focused on T
helper cells. Increasing evidence highlights the importance of the
CD8 T cell compartment in SIV/HIV disease progression (Tables 1
and 2). An increased frequency of persistent, circulating CD8 T cells
is associated with a higher risk of non-AIDS events (Mudd and
Lederman, 2014). Several studies have demonstrated that CD8 T
cell inﬁltration of the intestine is linked to memory CD4 T cell deple-
tion in acute SIV infection of RMs (Veazey et al., 1998), (Mattapallil
et al., 2005), (Wang et al., 2013). During acute SIV infection of Chi-
nese RMs, we observed in the ileum LP an increase of CD8 T cell num-
bers concomitant with enhanced expression of T cell attracting
chemokines, associated with a transient decrease in circulating CD8
T cells (Ponte, 2014). These results suggest that a shift in circulating
CD8 T cell homing to the gut mucosa had occurred. In addition, the
colon of acutely SIV-infected RMs was characterized by perforin
overexpression, suggesting a strong cytotoxic response during
early infection (Quigley et al., 2006). In chronic SIV infection, the
presence of speciﬁc cytotoxic T cells in the intestine correlated
with preserved CD4 T cell counts (Schultheiss and Stahl-Hennig,
2011), highlighting the role of the CD8 T cell speciﬁc immune re-
sponse in maintaining mucosal integrity.
An expansion of total CD8 T cells was also reported in the rectal
mucosa of SIV-infected RMs; upon further investigation, it was dem-
onstrated that increased numbers of CD8 Treg (CD8+ FOXP3+)
persisted during chronic SIV infection (Nigam et al., 2010). Although
CD4 Th17 cells are considered to be the main source of interleukin
(IL)-17 and IL-22, recent studies have revealed that Tc17 cells, a sub-
set of CD8 T cells that produce IL-17, aremaintained in the gut of RMs
during acute SIV infection and are progressively depleted during the
chronic stage (Nigam et al., 2011), (Xu et al., 2012). These results in-
dicate that, in addition to the CD4 Th17/Treg ratio, an altered balance
between Tc17 cells and CD8 Treg characterizes progressive SIV and
HIV infections.3.4. Intestinal Innate Immune Cell Dysfunction in SIV/HIV Infection:
Disturbed Crosstalk Between Innate and Adaptive Immunity
3.4.1. Innate Lymphoid Cells: New Players in the Field of Gut Damage
Innate lymphoid cells (ILCs) are a growing group of immune cells
enriched at mucosal surfaces that mirror the phenotypes and functions
of T cells (Eberl et al., 2015). Conversely to T cells, ILCs do not express
acquired antigen receptors or undergo clonal selection and expansion
upon stimulation. Instead, ILCs react promptly to signals from infected
tissues by secreting cytokines. ILCs have been classiﬁed into three
main types based upon their cytokine responses and transcription fac-
tors that regulate their function. Type 1 ILCs (ILC1) secrete Th1-related
cytokines such as interferon-γ (IFN-γ) and tumor necrosis factor
alpha (TNF-α) and promote immunity against intracellular pathogens.
ILC2 produce type 2 cytokines (IL-4, IL-5) and play a signiﬁcant role in
response to helminth infection. ILC3 produce IL-17 and IL-22 and ex-
press the transcription factor RORγt, (Spits et al., 2013). Thus, ILC3
share effector functions with Th17 cells, although performing their
functions in the absence of antigen speciﬁcity (Artis and Spits, 2015).
Convergent study ﬁndings of Indian RM have shown that IL-17-
producing ILCs are rapidly and persistently depleted in the GI tract fol-
lowing SIV infection (Xu et al., 2012; Li et al., 2014; Xu et al., 2015).
Xu et al. identiﬁed translocated microbial products as a driver of ILC ap-
optosis through TLR-mediated signaling. Furthermore, both colonic and
circulating blood ILC3 are decreased in HIV-infected individuals and
predict disease progression (Zhang et al., 2015). The identiﬁcation of
ILCs represents a paradigm shift in mucosal immunology as these cells
established a bridge betweenmicroenvironment and adaptive immuni-
ty and are severely damaged during SIV/HIV infections.
3.4.2. Intestinal Macrophages: Supplanting the Silent Sentinels
Intestinal macrophages are strategically located in the LP lining the
epithelium. These cells can efﬁciently perform phagocytic and bacteri-
cidal functions without inducing inﬂammation (Smith et al., 2005). In
healthy gut mucosa, macrophages express toll like receptor-4 (TLR-4),
do not express CD14, the co-receptor for gram-negative bacteria lipo-
polysaccharide (LPS), and do not produce inﬂammatory cytokines
such as TNF-α, IL-6 or CXCL10 (Smith et al., 2010). Therefore, gut mac-
rophages are critical for protecting epithelium integrity. These cells also
express low levels of CD4 and of the HIV co-receptors CCR5 and CXCR4,
thereby reducing their susceptibility to HIV infection, and do not seem
to support HIV replication (Shen et al., 2009).
Numerous studies have observed that SIV and HIV induce intestinal
myeloid cell dysfunction, depicted in Tables 1 and 2, respectively. Gut
macrophages with defective phagocytic function were observed by
Estes et al. in chronically, but not acutely, SIV-infected Indian RMs
(Estes et al., 2010). This observation could explain the limited microbial
translocation observed in acute SIV/HIV infections during which time
gutmacrophages are still capable of effectively phagocytosingmicrobial
products.
As intestinal resident macrophages have reduced proliferative ca-
pacity, the recruitment of circulating monocytes is likely the main
source for their renewal.While the pro-inﬂammatory CD16+monocyte
subset is expanded in SIV-infected RMs, the number of these cells
remains stable in nonpathogenic infection of SMs. These observations
suggest that CD16+ monocytes contribute to SIV/HIV pathogenesis. In
chronically HIV-infected individuals, inﬂammatorymonocytes accumu-
late in the LP of the duodenum in response to increased mucosal levels
of the CCL2 chemokine (Allers et al., 2014). Furthermore, CD14+macro-
phages accumulate in the colon of AIDS patients and correlate with the
degree of microbial translocation (Cassol et al., 2015).
Collectively, these observations indicate that the inﬁltration of
pro-inﬂammatorymonocytes into the intestinal mucosa during SIV/HIV
infections, which results in the development of tissue-resident macro-
phages, promotes local inﬂammation and tissue injury; this process re-
sults in further recruitment of circulatingmonocytes. Moreover, the low
44 R. Ponte et al. / EBioMedicine 4 (2016) 40–49phagocytic activity of the resulting macrophages prevents efﬁcient
purging of microbial products, resulting in increased microbial translo-
cation across the injured intestinal barrier.
3.4.3. Neutrophil and Dendritic Cell Contribution to Gut Damage
Among the other immune cells in the gut mucosa are polymorpho-
nuclear neutrophils (PMNs) and dendritic cells (DCs), whose contribu-
tions to gut damage in SIV/HIV infections have not been well studied.
The results of studies that have been performed are summarized in
Tables 1 and 2.
PMNs contribute to theﬁrst line of defense against bacterial and fun-
gal pathogens. These cells rapidlymigrate to the inﬂamed tissues where
their activation triggers the release of antimicrobial peptides and pro-
teolytic enzymes such asmyeloperoxidase. During chronic SIV infection
of RMs, neutrophils, which were shown to have inﬁltrated the colonic
mucosa, were linked to epithelial barrier damage (Estes et al., 2010).
Neutrophils were also reported to have invaded the rectal mucosa of
RM four weeks after SIV infection (Pallikkuth et al., 2013). In contrast,
Hensley-McBain et al. did not report increased PMN counts within the
ﬁrst 28 days following SIV infection of RMs, which was likely due to a
lack of PMN-supporting cytokines (Hensley-McBain et al., 2014). Fur-
thermore, circulating neutrophils are more prone to undergo apoptosis
during pathogenic SIV infection as compared to nonpathogenic models
(Elbim et al., 2008). Therefore, while the virus itself may not induce
PMN accumulation during early infection, some lines of evidence
point to PMN inﬁltration during chronic SIV/HIV infections, suggesting
that PMNs might contribute to inﬂammation and gut barrier damage
during the chronic phase.
In contrast to neutrophils, which are recruited by the inﬂamed mu-
cosa, DCs are resident cells that are diffusely located throughout the
LP, within Peyer's patches and in isolated lymphoid follicles. Intestinal
DCs include CD123+ plasmacytoid DCs (pDCs) and CD11c+ myeloid-
derived DCs (mDCs). pDCs are a major source of IFN-α, providing aTable 3
Studies of early changes in intestinal cytokine/chemokine networks in SIV-infected rhesus mac
Gut segment Time post-infection Cytokine/chemokine Change Source
Small intestine Acute CCL19 (MIP-3β), CXCL9 Increase LPLa
Jejunum Day 21 Th1 and Th2 cytokines
IL-17, IFN-γ, GM-CSF, MIF
Decrease
Increase
CD4 T
CD8 T
Ileum Day 2–3 IL-1β Increase Paneth
Jejunum,
colon
Day 28 IL-10
TNF-α
IFN-γ
Increase
Increase
Increase
T cells
T cells
NK, ma
Th1 an
NK cel
Jejunum Acute IFN-α
CXCL8 (IL-8)
IL-12
IL-17, IL-22
IL-23
Increase
Increase
Increase
Increase
Increase
Tcells,
T cells,
Monoc
Th17 c
Macrop
Small
intestine
Days 3 to 10
Days 7 to 14
IL-7
CCL5 (RANTES)
CCL25 (TECK)
CXCL10 (IP-10)
Increase
Increase
Increase
Increase
ECsb
T cells
ECsb
Monoc
endoth
MIP-3β: macrophage inﬂammatory protein-3beta; LPL: lamina propria lymphocytes; IL: interl
macrophage migration inhibitory factor; TNF: tumor necrosis factor; DCs: dendritic cells; ECs: e
cells; RANTES: regulated on activation, normal T cell expressed and secreted; TECK: thymus-exp
Chinese origin and (In): rhesus macaque of Indian origin, when applicable.
a As indicated in the study
b As indicated in the literature.ﬁrst line of defense against HIV (Bruel et al., 2014). Studies of SIV infec-
tion have demonstrated that IFN-α and TNF-α producing pDCs accumu-
late in the gutmucosa and participate in the ongoing immune activation
instead of controlling initial SIV dissemination (Li et al., 2015; Reeves
et al., 2012). In another study, a subset of DCs that expressed CD103
(integrin αE), was found to be depleted in the colon, while no change
was observed in mDC or pDC frequencies (Klatt et al., 2012). These
contrasting results highlight the need to clarify the contribution of DCs
to the gut mucosal inﬂammation that occurs during SIV infection.
3.5. Altered Chemokine/Cytokine Microenvironment: Do Recruited Soldiers
Become Prey for SIV/HIV?
Numerous studies have shown that intestinal tissues exhibit altered
chemokine and cytokine networks due to SIV infection; the results of
these studies are summarized in Table 3. CCL20 and CCL21 chemokines
associated with the trafﬁcking of DCs, B and T cells are unchanged dur-
ing the course of SIV infection (Choi et al., 2003), while CCL19 and
CXCL9 are up-regulated in the small intestine of RMs during acute infec-
tion and are associated with the recruitment of CD4 T cells (Clay et al.,
2005), potentially feeding viral replication. Tissue CD8 T cell counts in-
crease during SIV infection and these cells secrete CCL5 (a CCR5 ligand)
and GM-CSF into the small intestine (Kenway-Lynch et al., 2013), sug-
gesting that DCs, monocytes/macrophages, T cells, B cells, as well as
neutrophils, could be rapidly recruited to the gut. Importantly, in-
creased expression of CCL5 could be implicated in the exacerbation of
HIV pathogenesis (Zhou et al., 2011).We have also evidenced enhanced
expression of gut-expressed CCL25, which recruits CCR9+ effector T
cells, and IFN-γ induced CXCL10, which has the potential to attract
monocytes/macrophages, DCs, and T and B cells, in acute SIV infection
of RMs (Ponte, 2014).
Furthermore, several studies have demonstrated increased levels of
pro-inﬂammatory cytokines such as IL-1β, TNF-α, IFN-α, IFN-γ, IL-8 andaques.
References
Clay et al., 2005
cellsa
cellsa
Kenway-Lynch et al., 2013
cellsa Hirao et al., 2014
, B cells, monocytes/macrophages, DCs, ECsa
, B cells, monocytes/macrophages,
st cells, endothelial cells, ECsb
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eukin; IFN: interferon; GM-CSF: granulocyte macrophage colony stimulating factor; MIF:
pithelial cells; NK: natural killer; NKT: natural killer T cells; pDCs: plasmacytoïd dendritic
ressed chemokine; IP-10: interferon gamma-induced protein 10.; (Ch): rhesusmacaque of
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munomodulatory IL-10 (Pan et al., 2014) and transforming growth fac-
tor beta (TGF-β), (Reeves et al., 2011) are also observed in SIV infection,
suggesting that these cytokines were not able to induce anti-
inﬂammatory responses. Importantly, in experimental SIV infection of
SM and AGM natural hosts, the evaluation of plasma cytokine levels in
early infection showed that the absence of immune activation was due
to a signiﬁcant downregulation of inﬂammatory cytokines rather than
a lack of early inﬂammation (Pandrea and Apetrei, 2010).
3.6. Structural Gut Damage Causes Leakage of a Modiﬁed Gut Microbiota
3.6.1. Epithelial Barrier Disruption: Creating Breaches for Microbial
Invaders
The intestinal epithelium, made of a single layer of enterocytes to-
gether with a luminal mucus layer, provides a physical and chemical
barrier between the host and the so-called “extended-self” luminal
microbiome. The chemical barrier includes soluble factors such as IgA
and defensins. Epithelial cells establish close contact at their lateral
cell membranes by dynamic structures named tight junctions, which in-
terconnect the cells and restrict the passage of bacterial products
through the paracellular space. Intestinal epithelial cells express the
IL-22 receptor, which plays an important role in the renewal of the
gut barrier (Aujla and Kolls, 2009).
Damage to the gut barrier involves the apoptosis of enterocytes dur-
ing the acute stage of SIV infection, which persists in the chronic phase
(Li et al., 2008; Pan et al., 2014). Li et al. reported massive SIV-induced
epithelial cell apoptosis as an underlyingmechanismof the regenerative
enteropathy that characterizes early SIV infection. Consistently, another
study described enhanced epithelial cell proliferation during SIV infec-
tion, as a repair mechanism triggered in response tomassive enterocyte
death (Mohan et al., 2013). In contrast, impaired epithelial proliferation,
which was detected in the colorectal tissues of HIV-infected patients,
was linked to increased apoptosis (Somsouk et al., 2015). Therefore, it
remains unclear whether mucosal apoptosis in ART-treated individuals
is a cause or a consequence of epithelial proliferative changes.
Moreover, the rapid, SIV-induced secretion of IL-1β correlated with de-
creased expression and with mislocalization of tight junction proteins
(Hirao et al., 2014).
Thus, during SIV/HIV infections, damage to the physical integrity of
the epithelium causes breaches in the gut barrier that increases intesti-
nal tract permeability, resulting in the passage of luminal microbiota
products through the mucosa into the systemic circulation (Estes
et al., 2010).
3.6.2. Microbiota Changes and Inﬂammation Throughout the Gut Barrier: A
Two-way Street
Studies of untreated HIV-infected individuals have revealed altered
composition of the fecal microbiota in which pathogenic bacteria such
as proteobacteria species were found at higher levels than probiotics
such as Lactobacilli (Gori et al., 2008); this ﬂora modiﬁcation persisted
during short-term ART (Nowak et al., 2015). Furthermore, several
groups have reported an alteredBacteroides/Prevotella ratio in untreated
HIV-infected persons (Lozupone et al., 2013), detected in gut epithelium
adherentmicrobiota (Dillon et al., 2014). Dysbiosis of the gutmicrobiota
and changes in their dietary tryptophan catabolite by-productswere as-
sociated withmucosal and systemic immune activation, contributing to
disease progression (Vujkovic-Cvijin et al., 2013; Dillon et al., 2014;
Routy et al., 2015), suggesting that gut-resident microbial communities
inﬂuence HIV pathogenesis. NHP models, which have permitted the
longitudinal sampling of feces throughout SIV infection, have dimin-
ished the bias attributed to differences in diet. In contrast to ﬁndings
in human studies, SIV infection did not cause signiﬁcant alterations of
the fecal and gut-associated bacteriome (Handley et al., 2012), with
dysbiosis, characterized by an enrichment of proteobacteria that may
preferentially translocate, observed only in ART-treated macaques(Klase et al., 2015). However, a recent study of untreated acute SIV in-
fection of RMs demonstrated speciﬁc depletion of Lactobacilli,
supporting previous ﬁndings in HIV-infected persons (Vujkovic-Cvijin
et al., 2015). This diminution of Lactobacilli was associated with in-
creased activity of the tryptophan-catabolizing immunosuppressive en-
zyme indoleamine 2,3-dioxygenase 1 (IDO1) and with Th17 loss,
suggesting that Lactobacillus species inhibit IDO1 activity as a mecha-
nism to maintain mucosal immune homeostasis. Importantly, these re-
sults highlight the need for new therapeutic strategies to regulate both
metabolic activity and composition of the intestinal ﬂora.
3.6.3. Microbial Translocation and Biomarkers of Gut Damage
SIV-induced gut damage and subsequent microbial translocation
have been linked for the ﬁrst time to systemic immune activation in
chronically SIV-infected Indian RMs (Brenchley et al., 2006; Estes
et al., 2010). In these seminal studies, plasmatic bacterial LPS levels cor-
related with activation markers such as T cell CD38 and HLA-DR, and
with plasma soluble CD14 (sCD14), which is released by activated
monocytes. The effect of gut damage and microbial translocation on
pathogenic immune activation was demonstrated in uninfected pigtail
macaques (Klatt et al., 2010) and in experimentally-induced colitis in
RMs (Hao et al., 2015). This latter study demonstrated the value of a
non-invasive clinical monitoring technique to assess intestinal micro-
vasculature leakage in IBDandHIVpatients. Furthermore, earlyHIV infec-
tion has been associated with higher levels of LPS-binding protein (LBP)
and with intestinal fatty acid binding protein (I-FABP), a marker of
enterocyte damage (Marchetti et al., 2013).
Clearly, numerous complex mechanisms contribute to gut damage
that occurs following SIV/HIV infections (summarized in Fig. 1). We
propose that therapies targeting the composition andmetabolic activity
of the GI microbiota, which are altered in HIV-infected individuals,
could beneﬁt ART-treated individuals.
4. Strategies to Restore the Integrity of the Gut Barrier
4.1. Early ART is Not Sufﬁcient to Fully Restore Gut Damage
Wehave previously reviewed the results of several clinical trials that
investigated the effect of early ART on gut dysfunction (Cao et al.,
2015b). Importantly, early ART initiation preserved Th17 function and
reversed immune activation, as deﬁned by the expression of the T cell
activation markers CD38 and HLA-DR. However, gut damage, which
was assessed by measuring plasma I-FABP and LPS levels, was not
reversed by early ART, suggesting ongoing enterocyte damage and sub-
sequent bacterial translocation (Jenabian et al., 2015). We and others
have reported that initiation of ART during acute infection preserved
mucosal CD4 T cells without reducing CD8 T cell inﬁltration (Allers
et al., 2015; Cao et al., 2015a). These data indicate that mucosal damage
was not completely prevented or reversed by early ART initiation,
implying that damage to other cells in addition to CD4 T cells in
the gut is needed to lead to a signiﬁcant augmentation of bacterial
translocation.
4.2. Targeting Gut Microbiota and Repairing the Breaches: Rebuilding
Harmony
The combination of sulfasalazine, an anti-inﬂammatory molecule,
and the antibiotic rifaximin, signiﬁcantly reduced immune activation
in SIV-infected pigtail macaques (Marchetti et al., 2013). However,
long-term antibiotic therapies may result in the emergence of resistant
microbes and in further injury to the gut barrier. Another therapeutic
option that has been investigated in a fast-progressing, SIV-infected pig-
tailedmacaquemodel, consists of neutralizing translocated gutmicrobi-
al products using the LPS-binding drug sevelamer (Kristoff et al., 2014).
This treatmentwas associatedwith reduction of SIV-induced inﬂamma-
tion, immune activation and coagulation markers, providing an
Fig. 1. Schematic representation of the multiple mechanisms that induce gut damage following SIV/HIV infections and strategies to reduce mucosal inﬂammation. Gut damage includes
alterations to themicrobiota, injuries to the gut epithelium, and changes to the immunemucosal landscape, all of which lead to persistent inﬂammation and systemic immune activation.
Lymphoid cellular damage, which occurs in early infection, consists of CD4 T cell depletion, an altered Th17/Treg ratio, the loss of IL-17 producing innate lymphoid cells (ILCs),
accumulation of CD8 T cells, and monocyte activation. These changes, which persist during disease progression, are accompanied by myeloid changes such as macrophage
accumulation and defective phagocytosis, neutrophil and pDC inﬁltration, and the loss of CD103+ DCs. The loss of IL-17-producing CD8 T cells (Tc17 cells) also characterizes the
chronic phase of infection. Overproduction of kynurenine (Kyn) metabolites from dietary tryptophan (Trp) by the immunosuppresive enzyme indoleamine 2,3-dioxygenase (IDO)
contributes to an altered Th17/Treg ratio. Strategies to reduce mucosal inﬂammation are depicted in red.
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immune activation. However, in individuals with untreated early HIV
infection, sevelamer administration did not inﬂuencemicrobial translo-
cation and inﬂammation, possibly reﬂecting low LPS translocation
during this period of infection (Sandler et al., 2014).
The use of ART highly effective in suppressing SIV replication in
macaques has permitted the assessment of microbiota modulating
strategies, involving probiotic bacteria and/or prebiotic nutrients.
Remarkably, following treatment with a combination of probiotics, GI
tract CD4 T cells were reconstituted in ART-treated, SIV-infected RMs(Klatt et al., 2013). Moreover, administration of commensal Lactobacillus
plantarum directly into the intestine of SIV-infected macaques led to the
decreased secretion of IL-1β by Paneth cells, in addition to epithelial
tight junction repair (Hirao et al., 2014), suggesting that reduced
inﬂammation is associated with gut barrier restoration. Encouragingly,
probiotic/prebiotic therapies were also associated with immune beneﬁts
in ART-treated patients; however large, placebo-controlled clinical trials
are necessary to assess the long-term efﬁcacy of these therapies
(reviewed in Brenchley, 2013). Finally, a more holistic picture may be re-
quired to treat SIV/HIV-induced gut damage given that certain microbes
47R. Ponte et al. / EBioMedicine 4 (2016) 40–49cohabit in a reciprocal relationship with parasitic helminths within the
mammalian GI tract (Reynolds et al., 2015).
4.3. Immune-based Therapies for the Treatment of SIV/HIV-induced Gut
Damage
Immune-based therapies designed to reduce intestinal inﬂamma-
tion and subsequent systemic immune activation have been investigat-
ed in RMs and in humans. While anti-TNF-α treatment successfully
decreased the expression of proinﬂammatory genes and lowered the in-
ﬁltration of PMNs into lymphoid tissues during early SIV infection, no
change in viral load was reported (Tabb et al., 2013), further arguing
for the need to combine such anti-inﬂammatory strategies with
ART. The common use of serum-derived bovine immunoglobulin to ef-
ﬁciently reduce intestinal inﬂammation in animal models was the
rationale to implement a pilot clinical trial in ART-treated adults.
These individuals experienced intestinal immune reconstitution and
epithelial repair in the setting of HIV enteropathies (Asmuth et al.,
2013). These early ﬁndings highlight the value of therapy designed to
repair both immune and epithelial GI tract compartments.
The immune inhibitory receptor programmed death-1 (PD-1)
regulates the functional exhaustion of virus-speciﬁc CD8 T cells during
SIV/HIV infections (Trautmann et al., 2006). PD-1 blockade in SIV-
infected RMs resulted in a lower plasma viral load and in reduced ex-
pressionof transcripts associatedwith IFN signaling in the blood and co-
lorectal tissue (Dyavar Shetty et al., 2012). Furthermore, these ﬁndings
were associated with enhanced expression of gut-junction associated
genes in colorectal tissue along with lower plasma LPS levels, suggest-
ing immune improvement of both SIV-speciﬁc and mucosal immunity.
However, blocking the PD-1 pathway in SIV-infected macaques con-
ducted by another group showed limited clinical beneﬁt, generating
the hypothesis that blocking a single inhibitory pathway may not be
sufﬁcient to control SIV/HIV-induced exhaustion (reviewed in Velu
et al., 2015).
The success of metformin treatment in attenuating IBD severity and
in regulating the Th17/Treg ratio inmice (Lee et al., 2015), alongwith its
routine use in diabetic patients, has led to the design of a clinical trial
that will assess whether metformin can reduce inﬂammation in
HIV-infected individuals. To modulate the Th17/Treg ratio, IDO inhibi-
tors such as 1-methyl-D-tryptophan were also administered to ART-
treated, SIV-infected RMs; this treatment reduced plasma viral load
only in macaques that did not receive any immunological beneﬁt from
ART (Boasso et al., 2009). Therefore, more studies are required to deter-
mine whether such an approach may be beneﬁcial for the treatment of
HIV infection.
Given the signiﬁcant changes that occur in the chemokine network
and in cell migration within the gut mucosa following SIV infection,
strategies that target the gut-homing α4β7 integrin expressed by T
cells have been investigated in RMs (Byrareddy et al., 2014). In this
study, administration of an anti-α4β7 monoclonal antibody reduced
SIV transmission and protected gut mucosal CD4 T cells from infection.
Encouragingly, SIV transmission was also reduced by the use of the
CCL20 chemokine inhibitor glycerol monolaurate (Li et al., 2009).
Other immune-based treatments that have been investigated for the
treatment of SIV/HIV-mediated gut damage involved common gamma
chain cytokines such as IL-7 and IL-21. ART-treated, SIV-infected RMs
that received IL-7 demonstrated increased numbers of peripheral CD4
T cells (Beq et al., 2006); a similar effect was observed in HIV-infected
patients (Levy et al., 2012). This therapy was shown to trigger chemo-
kine expression in intestinal tissues as well as chemokine receptors
and α4β7 integrin expression by circulating cells, leading to massive T
cell homing to the gut mucosa, and decreased colonic inﬂammation
(Beq et al., 2009; Cimbro et al., 2012; Sereti et al., 2014).
IL-21 is a pleiotropic cytokine that induces Th17 cell differentiation
and that promotes CD8 T cell cytotoxic function. Pallikkuth et al. have
shown that IL-21 treatment of SIV-infected RMs increased Th17 cellfrequency and enhanced the cytotoxic function of total and SIV-
speciﬁc CD8 T cells (Pallikkuth et al., 2013). Such immune improve-
ments were associated with reduced microbial translocation and with
a long lasting reduction in immune activation in the blood and in the
rectum. Similar results were obtained in another study in which IL-21
and probiotics were concurrently administered to ART-treated, SIV-
infected pigtailed macaques (Ortiz et al., 2015). Importantly, this treat-
ment led to increased gut CD4 T cell frequencies without altering viral
suppression by ART. Interestingly, a reduction in the size of the viral res-
ervoir was detected in ART-treated RMs receiving IL-21 (Micci et al.,
2015). Currently, IL-21 is being investigated as an immunomodulatory
cytokine in cancer patients and in HIV-infected persons.
5. Conclusion
SIV infection studies have contributed to a better understanding of
the detrimental role of gut damage in HIV pathogenesis. HIV infection
induces important damages in lymphoid, myeloid and stromal cell gut
compartments, while causing dysbiosis of microbial communities.
These signiﬁcant pathological changes induce the loss of gut barrier in-
tegrity, creating an “immune scar” that persists during chronic infection
and that contributes tomicrobial translocation and inﬂammation,while
increasing the risk of non-AIDSmorbidities.We believe that, in addition
to early ART initiation,modulation of themicrobiotawith probiotics and
repairing gut damage with immune-based therapies have produced
promising results that warrant future investigations to control residual
inﬂammation and reduce viral reservoirs in persons living with HIV.
6. Outstanding Questions
The proﬁcient development of therapies for reversing gut damage in
HIV-infected individuals will rely on the scientiﬁc andmedical commu-
nity to address major issues. First, the key to elucidate mechanisms of
gut barrier integrity restoration may rely in our further understanding
of the disparities between pathogenic and nonpathogenic SIV infec-
tions. Given the absence ofmicrobial translocation in the latter, mucosal
defense pathways are certainly preserved and more work is needed to
assess the essential determinants for the persistence of gut integrity in
a context of viral replication in natural hosts. Second, it becomes imper-
ative to determine the role of the gut microbiota in HIV-induced gut
damage and downstream inﬂammation. Future studies on gutmicrobial
metabolites together with the development of metagenomic ap-
proaches may bridge the gap in our current knowledge, coupling gut
microbiota composition, epithelial integrity and immune responses.
On a clinical perspective, orchestrating the assessment of gut biopsies
and their associated “local”microbiota aswell as feces from large cohort
of patients would certainly broaden our understanding of microbial-
host interaction associated with epithelial and immune damage. Ulti-
mately, a better characterization of the persistence of gut damage
even after early ART initiation is warranted to identify the mechanisms
responsible for this residual alteration. Althoughﬁndings on antiretrovi-
ral pharmacodynamics in the GI tract were not discussed in this review,
important data are missing in order to delineate whether incomplete
gut epithelial restoration could be due to low drug concentrationwithin
this compartment. Notably, future studies should also address to what
extent gut reconstitution is required for HIV-infected individuals to
achieve full protection against co-morbidities.
7. Search Strategy and Selection Criteria
We conducted a comprehensive literature review of English
language publications in PubMed electronic database in which we
searched for references for relevant articles; the search terms used
were “acute SIV/HIV infections”, “gut T cell”, “innate lymphoid cells”,
“intestinal macrophages”, “dendritic cells”, “neutrophils”, “epithelial
damage”, “microbiota”, “microbial translocation”, and “cytokine
48 R. Ponte et al. / EBioMedicine 4 (2016) 40–49therapy”. Except for seminal studies, only articles published between
2005 and 2015 were included.
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